BridgeBio Pharma, Inc. (BBIO) Social Stream
BridgeBio Pharma Inc (BBIO) Price Targets From Analysts
Use the tables below to see what analysts covering BridgeBio Pharma Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 39 weeks, BBIO's average price target has gone down $43.
BBIO reports an average of 52.82% for its upside potential over the past 51 weeks.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
BBIO Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 19 months, BBIO's average broker recommendation rating worsened by 0.02.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for BBIO as an investment opportunity.
- In the context of all US stocks, BridgeBio Pharma Inc's upside potential (average analyst target price relative to current price) is higher than 287.11% of them.
- In the context of Pharmaceutical Products stocks, BridgeBio Pharma Inc's variance in analysts' estimates is lower than -46.51% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, BridgeBio Pharma Inc's average analyst price target is higher than 228.42% of them.
- BridgeBio Pharma Inc's number of analysts covering the stock is greater than 212.13% of Pharmaceutical Products stocks.
Make investment decisions regarding BBIO using the data that counts. Try POWR Ratings for free.